| Section | Provisional content | Verification needed |
|---|---|---|
| Retrieval failure note | Tool-based literature retrieval was blocked in this session: no retrievable papers and no citable context IDs were returned, so this is a **seed-only, provisional** summary rather than a fully cited 2023–2024 review. Seed PubMed URLs: PMID:25062452 — https://pubmed.ncbi.nlm.nih.gov/25062452/ ; PMID:32402064 — https://pubmed.ncbi.nlm.nih.gov/32402064/ ; PMID:34718620 — https://pubmed.ncbi.nlm.nih.gov/34718620/ ; PMID:35718780 — https://pubmed.ncbi.nlm.nih.gov/35718780/ | Confirm full texts, figures/tables, and any newer 2023–2024 studies manually. |
| 1. Executive judgment | **Partially supported (provisional).** Seed evidence is consistent with biallelic or otherwise damaging **SYCE1** variants causing meiotic failure via synaptonemal-complex dysfunction, but support cannot be fully graded without direct review of the papers. | Reassess support level after full-text review of all seed papers. |
| 2. Evidence matrix | Seed evidence spans four classes: human familial genetics (**25062452**), model-organism/functional evidence (**32402064**), in vitro interaction plus human cohort evidence (**34718620**), and human NOA histology/CNV evidence (**35718780**). | Extract methods, sample sizes, controls, and exact claims from each paper. |
| 3. Clinical spectrum summary | **46,XX:** primary ovarian insufficiency / primary amenorrhea. **46,XY:** non-obstructive azoospermia with reported pachytene-stage spermatogenic arrest on H&E/IF. Detailed hormone, imaging, and pathology data were not retrievable here. | Verify FSH, AMH, LH, estradiol, testosterone, inhibin B, ovarian imaging, follicle depletion, semen data, and biopsy markers. |
| 4. Variant and inheritance summary | Provisional model: **autosomal recessive / biallelic**. Seed mentions a **homozygous nonsense variant c.613C>T**, additional damaging variants affecting interactions, and **SYCE1 CNVs**. | Confirm exact nomenclature, transcript reference, zygosity/phasing, segregation, CNV breakpoints, family counts, and ACMG/ClinVar status. |
| 5. Mechanistic causal chain | Provisional chain: **biallelic SYCE1 loss/damaging variant → reduced/absent SYCE1 → disrupted interaction with SYCP1 and/or C14ORF39/SIX6OS1 → SC central element assembly failure → homologous synapsis failure → pachytene arrest/checkpoint activation → germ-cell depletion → POI or NOA phenotype**. | Determine which links are direct in humans versus inferred from model/in vitro work; verify SC markers and arrest/checkpoint evidence. |
| 6. Diagnostics and management implications | Provisional implications: include **SYCE1** on infertility/POI/NOA panels with **CNV detection**; in 46,XY consider semen analysis, endocrine workup, and biopsy when indicated; in 46,XX assess ovarian reserve and POI biochemistry. Management likely follows standard POI/NOA care pathways. | Check whether papers report fertility outcomes, HRT use, fertility preservation, micro-TESE/ICSI results, or counseling details. |
| 7. Ontology suggestions by label only | **HPO:** Primary ovarian insufficiency; Primary amenorrhea; Female infertility; Azoospermia; Non-obstructive azoospermia; Spermatogenic arrest; Hypergonadotropic hypogonadism. **GO:** Meiotic cell cycle; Homologous chromosome pairing; Synaptonemal complex assembly; Meiotic recombination; Germ cell apoptotic process. **CL:** Primary oocyte; Spermatocyte; Pachytene spermatocyte; Germ cell. **Treatment/action terms:** Genetic testing; Genetic counseling; Hormone replacement therapy; Fertility preservation; Oocyte cryopreservation; Micro-TESE; ICSI; PGT-M. | Map only labels directly supported by verified phenotype/mechanism text. |
| 8. Knowledge gaps and weak claims | Major gaps: no full-text verification, no figure/table review, uncertain CNV zygosity/phasing, limited direct human evidence for checkpoint activation or apoptosis, and no retrievable 2023–2024 updates. | Separate human-direct support from model/in vitro inference and perform manual literature update. |
| 9. Curation leads | After verification, consider annotating: **meiotic synaptonemal-complex central element assembly defect**; dual-sex phenotype (**46,XX POI/primary amenorrhea**, **46,XY NOA/pachytene arrest**); **loss-of-function and CNV** mechanisms; and partner-interaction defects involving **SYCP1** and **C14ORF39/SIX6OS1**. | Verify exact wording, evidence thresholds, and whether newer studies modify the entry. |


*Table: This compact table summarizes a seed-only, provisional evaluation of the SYCE1 mechanism hypothesis, organized by the 9 required outputs plus a retrieval-failure note. It is paste-ready for curation and highlights what still needs manual verification from the seed PubMed records.*